[The role of oxidative stress in hemorrhagic stroke and restorative effects of Mexidol].

Objective: Identification of the role of oxidative stress in the development of disorders that occur in hemorrhagic stroke (HS, post-traumatic intracerebral hematoma), and the study of the effects of Mexidol on neurological and cognitive deficits in HS with an analysis of the relationship between the therapeutic effects of the drug in HS with its antioxidant effect.

Material And Methods: The study was carried out on mature outbred male rats weighing 260-280 g. HS was created by destruction of the brain tissue in the area of the , with the introduction of blood into the site of injury.

Assessment of Susceptibility of Outbred Albino Rats to the Formation of Depression-Like State of Learned Helplessness.

Learned helplessness (a model of depression-like state) was developed in rats by exposure to repeated inescapable electric stimulation and evaluated by the absence of attempts to escape when it could be performed. In randomly grouped outbred white rats, 37.5% animals after the above procedure meet the criterion of learned helplessness.

[Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].

Rats with experimental Parkinson's syndrome induced by seven-day intraperitoneal administration of rotenone at a dose of 2.75 mg/kg have an increased activity of prolylendopeptidase (EC 3.4.

Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models.

It has been found recently that monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol (Diol) demonstrates high antiparkinsonian activity in some animal models. We carried out an extended study of the antiparkinsonian activity of Diol in a set of relevant animal models. Diol (20mg/kg) exhibited an anticataleptogenic effect in the haloperidol-induced catalepsy model and restored motor activity in animals in the reserpine-induced model of oligokinesia.

[COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS].

Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease. Two regimes of hemantane and amantadine administration in a range of final concentrations 10⁻⁶-10⁻⁸ M were used either prior to or immediately after 6-OHDA introduction. MTT colorimetric assay was used to assess the viability of test cells.

PECULIARITIES OF THE EFFECT OF AMINOADAMANTANE DERIVATIVES ON ETHANOL-INDUCED ATAXIA. SEDATION. AND HYPERLOCOMOTION IN MICE.

The influence of two aminoadamantane derivatives representing low-affinity NMDA receptor antagonists, which show antiparkinsonian-like activity both in animal models and in patients with Parkinson's disease, have been studied in vivo on mice with acute ethanol-induced disorders. N-(adamant-2-yl) hexamethyleneimine hydrochloride (himantane) in doses of 5--20 mg/kg, i.p.

Anti-Parkinsonian Activity of Hemantane on a Model of Hemiparkinsonian Syndrome in Rats.

Hemantane demonstrated a pronounced antiparkinsonian activity in the model of hemiparkinsonian syndrome provoked in rats by unilateral intracerebral injection of 6-hydroxydopamine, which was comparable to efficacy of levodopa in decreasing the duration of cataleptogenic state and the degree of akinesia of the contralesional forelimb assessed in the cylinder test. In the stepping test, hemantane exerted a long-term effect in contrast to levodopa, which diminished its beneficial action to the treatment day 21. In the swing test, the behavior normalized only by hemantane.

[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].

Levodopa-induced heavy dyskinesia was modeled in rats with severe hemiparkinsonian syndrome induced by injection of 6-hydroxydopamine in the left medial forebrain bundle. It is established that the antidyskinetic effect of the injectable dosage form of a new antiparkinsonian drug hemantane (5 mg/kg) after a single intravenous administration is weaker than that of the most effective in clinical practice antidyskinetic drug amantadine (20 mg/kg). However, after five days of treatment, the effect of hemantane injections exceeded that of amantadine.

[Effect of hemantane on bioelectric activity of brain in mice with MPTP-induced Parkinson syndrome].

A single intraperitoneal injection of MPTP neurotoxin (30 mg/kg) in C57BL/6 mice causes desynchronization of EEG with a decrease of theta-1 activity and a growth of beta activity in the interval of 15-30 Hz. Subchronic administration of the new antiparkinsonian drug hemantane (injection form) in a dose of 10 mg/kg makes the power of MPTP-induced beta oscillations less pronounced and leads to its reliable decrease within 24 h. This effect of hemantane administration was manifested during the entire period of observations.

[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].

Presymptomatic (premotor) stage of Parkinson's disease has been modeled in rats by intranigral bilateral injections of neurotoxin MPTP. Three weeks after surgery, rats demonstrated cognitive deficit and depressive-like behavior without definite motor impairment. Pretreatment with hemantane (10 mg/kg) and the reference drug amantadine (20 mg/kg) 5 days before MPTP and further administration during 3 weeks after MPTP preserve cognitive function and prevented depressive disturbances in rats.

[Comparative study of himantane and amantadine effects in experimental intracerebral posttraumatic hematoma].

Effects of the novel antiparkinsonian drug himantane and amantadin were studied in rats with intracerebral posttraumatic hematoma. Drugs were administered first at 3.5 hours after surgery and then for 4 consecutive days.

[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].

Chronic administration of levodopa and benserazide (10 and 15 mg/kg, respectively) cause the development of dyskinesia in rats with model parkinsonian syndrome induced by injection of 6-hydroxydopamine in left substantia nigra. The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia. Chronic administration of levodopa and benserazide together with hemantane (10 mg/kg) slows down the development and decreases the magnitude of levodopa-induced abnormal involuntary movements as measured for limb, orolingual and rotatory movements.

[Association study of the SCN1 gene polymorphism and effective dose of lamotrigine].

An association between a polymorphism of the SCN1 gene, a therapeutical target of lamotrigine, and an effective dose (a blood plasma concentration) of the drug in patients with epilepsy has been studied. Fifty patients with different forms of epilepsy have been genotyped for the SCN1 IVS5N+5 G>A polymorphism using polymerase chain reaction. The distribution of allelic variants was as follows: 23 patients had the mutant homozygous genotype (V/V), 20 - the heterozygous genotype Wt/V and 7 were homozygous for the wild allele (Wt/Wt).

The effect of short-term administration of (-)-deprenyl and isatin on the expressions of some genes in the mouse brain cortex.

Background: Isatin (indoledione 2,3) is an endogenous indole found in the mammalian brain, peripheral tissues, and body fluids. It exhibits many neurophysiological and neuropharmacological effects. It shares some common molecular targets with (-)-deprenyl, a neuroprotective pharmacological drug.

[The possibilities of using himantane in the treatment of Parkinson's disease].

The domestic drug himantane has been used as a monotherapy in dosage 25 mg daily during 12 weeks in patients with Parkinson's disease. Patient's state has been assessed using clinical, electromyographic, electroneuromyographic, EEG and psychometric (UPDRS and other scales) methods. The preparation used is well tolerated, induces the significant decrease of movement disorders, i.

[Evidence for the neuroprotective properties of afobazole in experimental model of focal brain ischemia].

The neuroprotective effect of the new selective anxiolytic afobazole was evaluated in rats with ischemic stroke produced by the occlusion of the left middle cerebral artery, with simultaneous ligation of the ipsilateral carotid artery. Afobazole exhibits a protective effect in a dose range from 0.1 to 5.

[Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction].

Changes in the BDNF content in brain structures--hippocampus, hypothalamus, striatum, and frontal cortex--were determined in mice of different emotional-stress reaction phenotypes, which were subjected to emotional stress and treated by the selective anxiolytic afobazole. The changes were different in BALB/c and C57BL/6 mice. Afobazole exhibited a significant protector action against a decrease in the brain BDNF level caused by emotional stress in BALB/c mice.

Analysis of BDNF in brain structures of inbred mice with different phenotypes of mental and stress reaction.

The content of BDNF was measured in cerebral structures of intact C57Bl/6 and BALB/c mice in winter and spring. The level of cerebral neurotrophic factor in laboratory mice depended on genetic characteristics and chronobiological factors.

[Functional brain activity in patients with Parkinson's disease during amantadin-sulfate therapy].

An investigation of bioelectrical brain activity in 32 patients with akinetic-rigid and trembling-rigid forms of Parkinson's disease was conducted before and after treatment with amantadin-sulfate on the basis of spectral-coherent EEG analysis. Comparing to controls, EEG deviations, mainly related to the main rhythm, were observed in 93.75% patients.

[The effect of hemantane on the generative function and gonad morphology in rats].

Effect of the new potential antiparkinsonian drug hemantane (N-(adamant-2-yl)hexamethyleneimine hydrochloride) on the generative function and gonad morphology was studied in a group of male and female mongrel rats. The generative function was studied after peroral drug administration in a dose of 10 mg/kg (ED50) and 50 mg/kg (5 ED50): males were treated over a 60-day period of spermatogenesis, while females received the drug in the same doses over 15 days (three estrous cycles). The gonad morphology was studied after a 6-month treatment of experimental animals with hemantane in the same doses.

[The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro].

Chronic administration of a low dose of reversible monoamine oxidase (MAO) B inhibitors isatin or himantane (20 mg/kg) to mice during 21 day did not influence the enzyme activity assayed in isolated brain mitochondria. However in vivo sensitivity of brain MAO B to irreversible mechanism-based inhibitor deprenyl injected to animals right after the last administration of the reversible inhibitor sharply decreased. This suggests accumulation of these compounds (or their metabolites?) in the brain accompanied by increased protection of active site of MAO B against specific irreversible inhibitor.

[Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].

An experimental investigation of parkinsonism in rats and patients with initial forms of Parkinson's disease was performed by using methods of electromyography and electroneuromyography. Neurophysiologic peculiarities of reorganization of peripheral neuromotor apparatus and criteria for treatment efficacy were detected. The results obtained in the study allowed evaluating of an adequacy of adamantan-sulphate therapy either in the animal experiments and in patients with Parkinson's disease.

[Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].

The activity of the adamantane derivative PK-Merz and the new aminoadamantane derivative hemantane was studied by methods of electromyography and electroneuromyography in rats with a model of Parkinson syndrome induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The toxin produced an increase in the pulse conduction velocity (PCV) in the motor fibers of peripheral nerves and a decrease in the amplitude and frequency of the maximum muscle stress curve. A singe administration of both PK-Merz and hemantane produced unidirectional changes in the neuromyographic parameters and reduced the PCV down to a level in the control group.

[Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].

N-(Adamant-2-yl)hexamethyleneimine hydrochloride (hemantane) is a new potential antiparkinsonian drug with a complex mechanism of action. The drug exhibits the properties of a low-affinity blocker of the ion channels of NMDA receptors, increases the dopamine content in striatum, and inhibits monoamine oxidases (MAO-B). This combination of properties suggests that hemantane can also possess neuroprotector properties.